Sean Spencer, MD, PhD, Fellow ’20, Postdoc ’22 | Harnessing Gut Microbes to Heal Patients

Why It Matters

By turning the gut microbiome into a measurable, modifiable target, clinicians can prevent and treat infections and chronic diseases more precisely, opening a new therapeutic class with significant commercial and health‑outcome potential.

Key Takeaways

• Microbiome now clinically actionable thanks to new sequencing tools.
• FDA approved fecal‑based therapies for recurrent C. difficile infection.
• Culturomics enables growth of previously unculturable gut microbes.
• Oral capsule can sample entire gastrointestinal tract non‑invasively.
• Future therapies include defined microbial consortia and engineered probiotics.

Summary

Dr. Sean Spencer, a Stanford gastroenterologist and physician‑scientist, presented the emerging clinical frontier of gut‑microbe therapeutics. He outlined how advances in sequencing, culturing and sampling are moving the microbiome from a research curiosity to a practical diagnostic and therapeutic tool.

Three convergent technologies—"decode" (rapid stool metagenomic sequencing), "grow" (culturomics that can culture nearly any gut organism) and "probe" (ingestible capsules that sample the entire GI tract)—now allow clinicians to map, isolate, and interrogate microbial communities with unprecedented resolution. These tools turn the gut’s 500,000 genes and trillions of cells into actionable data within days.

Spencer highlighted antibiotic‑induced dysbiosis as a clear clinical problem, using cases of C. difficile infection, resistant bloodstream infections, and post‑transplant complications. He traced the evolution from historic fecal enemas to modern fecal microbiota transplantation, noting the FDA’s recent approval of two microbiome‑restoration drugs for recurrent C. difficile.

The talk underscored a paradigm shift: instead of merely killing pathogens, physicians must restore a balanced microbial ecosystem. Defined microbial consortia, engineered probiotics, and metabolite‑based “drugs from bugs” represent the next wave of scalable, regulated therapies that could reshape gastroenterology and broader disease management.

Original Description

Sean Spencer, MD, PhD, Fellow ’20, Postdoc ’22

Assistant Professor of Medicine–Gastroenterology and Hepatology

Discover the healing potential of the trillions of microbes that make up our gut microbiome. These microorganisms hold the key to pioneering innovative medicines designed to prevent and treat chronic conditions, including irritable bowel syndrome, inflammatory bowel disease, cancer, diabetes, and obesity. Dr. Spencer and a team of collaborators are building the tools, facilities, and clinical trials necessary to safely develop, test, and deliver new microbiome-based treatments to those who need them most.

Part Stanford Medicine Alumni Day 2026.